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Background: Gangliogliomas are low-grade glioneuronal tumors of the central nervous system and the commonest
cause of chronic intractable epilepsy. Most gangliogliomas (>70%) arise in the temporal lobe, and infratentorial tumors
account for less than 10%. Posterior fossa gangliogliomas can have the features of a classic supratentorial tumor or
a pilocytic astrocytoma with focal gangliocytic differentiation, and this observation led to the hypothesis tested in
this study - gangliogliomas of the posterior fossa and spinal cord consist of two morphologic types that can be
distinguished by specific genetic alterations.
Results: Histological review of 27 pediatric gangliogliomas from the posterior fossa and spinal cord indicated that they
could be readily placed into two groups: classic gangliogliomas (group I; n = 16) and tumors that appeared largely as a
pilocytic astrocytoma, but with foci of gangliocytic differentiation (group II; n = 11). Detailed radiological review, which
was blind to morphologic assignment, identified a triad of features, hemorrhage, midline location, and the presence of
cysts or necrosis, that distinguished the two morphological groups with a sensitivity of 91% and specificity of 100%.
Molecular genetic analysis revealed BRAF duplication and a KIAA1549-BRAF fusion gene in 82% of group II tumors, but in
none of the group I tumors, and a BRAF:p.V600E mutation in 43% of group I tumors, but in none of the group II tumors.
Conclusions: Our study provides support for a classification that would divide infratentorial gangliogliomas into two
categories, (classic) gangliogliomas and pilocytic astrocytomas with gangliocytic differentiation, which have distinct
morphological, radiological, and molecular characteristics.
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Gangliogliomas are rare mixed glioneuronal tumors, com-
posed of neoplastic glial and neuronal cells and represent-
ing 0.5-1.7% of all neuroepithelial tumors in the central
nervous system (CNS) [1-4]. However, they constitute up
to 4% of CNS tumors in the pediatric population and are
the commonest tumor associated with chronic intractable
focal epilepsy. Gangliogliomas are found throughout the
CNS, but most (>70%) are localized to the temporal lobe,
while they are uncommon in the posterior fossa (~5%)
and spinal cord (~3%) [2,5-9]. Gangliogliomas in the cere-
bral lobes are often circumscribed tumors and amenable* Correspondence: David.Ellison@stjude.org
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unless otherwise stated.to complete surgical resection, which is reflected in good
survival data [10]. Gangliogliomas in the posterior fossa or
spinal cord have a poorer outcome, but it is unclear
whether anatomic location or an inherent variance in bio-
logic behavior accounts for this difference [1,6,10].
Genetic alterations in elements of the mitogen-activated
protein kinase (MAPK) signaling pathway have been identi-
fied in many low-grade neuroepithelial tumors, including
pilocytic astrocytoma (PA), pleomorphic xanthoastrocytoma
(PXA), and ganglioglioma [11-14]. Recent studies have
demonstrated that specific mutations are enriched in certain
tumors; for example, KIAA1549-BRAF fusions are found in
PAs, and BRAF:p.V600E mutations are frequently detected
in PXAs (~70%) [14-19]. BRAF:p.V600E mutations are also
present in about one quarter of gangliogliomas [14].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Children’s Research Hospital, we occasionally review the
pathology of infratentorial gangliogliomas that demon-
strate the features of a classic pilocytic astrocytoma, ex-
cept for one or two collections of dysmorphic ganglion
cells that are clearly part of the neoplastic process. This
observation led to the hypothesis tested in this study;
gangliogliomas of the posterior fossa and spinal cord
consist of two morphologic types that can be distin-
guished by their molecular genetic alterations.
Methods
The study cohort consisted of 27 WHO grade I ganglio-
gliomas arising in the posterior fossa or spinal cord. Clin-
ical and radiological features were compiled (Table 1).
Median age at diagnosis was 10 years (range: 0.6 - 21
years), and the female:male ratio was 14:13. No patient
fulfilled clinical criteria for the diagnosis of NF-1. Review
of magnetic resonance imaging (MRI) was undertaken by
one radiologist, who was blinded to pathology review and
morphologic group assignment. Tumors were evaluated
radiologically on the following parameters: location (dom-
inant and secondary sites of involvement), relationship to
midline, circumscription, extent of edema and restricted
diffusion, and the presence of cysts or necrosis, he-
morrhage, and enhancement. The study was conducted
with St. Jude Children's Research Hospital Institutional
Review Board approval (XPD07-107).
Histology and immunohistochemistry
Standard histological preparations, 4 μm formalin-fixed
paraffin-embedded (FFPE) sections stained with hema-
toxylin & eosin were supplemented with immunohisto-
chemical preparations. Antibodies to the following proteins
were utilized for routine pathologic evaluation: glial fi-
brillary acidic protein (1:400, Dako M076101), synapto-
physin (1:400, Leica MCL-L-SYNAP-299), NEU-N (1:5000,
Chemicon MAB377), neurofilament protein (1:100, Dako
M076229), microtubule-associated protein 2 (MAP2
1:10,000, Sigma M4403), and Ki67 (1:200, Dako M7240).
Interphase fluorescence in situ hybridization (iFISH)
Dual-color iFISH was performed on 4 μm FFPE tissue
sections. Probes were derived from BAC clones (BACPAC
Resources, Oakland, CA), labeled with an AlexaFluor-488
or AlexaFluor-555 fluorochrome, and validated on normal
control metaphase spreads to confirm chromosomal loca-
tion. BAC clones RP11-96I22 and RP11-837G3 were used
to screen for BRAF duplication at 7q34 (control probe on
7p11, RP11-251I15 and RP11-746C13). RP11-837G3 and
RP11-948O19 were used in a ‘break-apart’ probe strategy
to screen for BRAF rearrangement. RP11-265 F21 and
RP11-297 N18 (ETV6), along with RP11-96B23 andRP11-948I15 (NTRK3), were used to screen for ETV6-
NTRK3 fusions.
Nucleic acid extraction and mutation analysis
Genomic DNA was extracted from 10 μm FFPE scrolls,
using the Maxwell® 16 Plus LEV DNA purification kit
(Promega, Madison WI), and total RNA was extracted
from FFPE scrolls using the Maxwell® 16 RNA FFPE
prototype extraction kit (Promega, Madison WI), accord-
ing to manufacturer’s instructions. BRAF:p.V600, KRAS:p.
G12, and KRAS:p.Q61 were sequenced in genomic DNA
using previously published primers [12]. PCRs were per-
formed using GoTaq® Long PCR Master Mix (Promega,
Madison, WI). All PCR products were visualized using 1%
agarose gels. Direct sequencing of PCR products was per-
formed using BigDye version 3.1 and a 3730XL DNA
analyzer (Applied Biosystems, Foster City, CA). Results
were screened using CLC Main Workbench sequence
analysis software version 6.0.2 (CLC bio, Cambridge, MA).
Real-time quantitative reverse-transcription PCR
(qRT-PCR) for KIAA1549-BRAF detection
First-strand cDNA was synthesized using 1 μg total
RNA in a 20 μL reaction mixture using the iScript
cDNA synthesis kit (Bio-Rad Laboratories, Hercules,
CA). The mixture was incubated at 25°C for 5 min, 42°C
for 30 min, and 85°C for 5 min. qRT-PCR was per-
formed using TaqMan reagents and the Applied Biosys-
tems 7500 Real-Time PCR system (Life Technologies,
Carlsbad, CA). Forward and reverse primers and Taq-
Man probes are listed in Table 2. KIAA1549-BRAF
probes were labeled with 6-carboxyfluorescein (6-FAM)
as a 5’ reporter dye and 6-carboxytetramethylrhodamine
(TAMRA) as the 3′ quencher dye. A 10 μL aliquot of
cDNA (corresponding to 100 ng of total RNA) was
added to the PCR reaction mix to reach a final volume
of 50 μL containing 25 μL of TaqMan Fast Universal
PCR Master Mix (2X) (Roche Diagnostics, Indianapolis,
IN), 300 nM of each forward and reverse primer, and 50
nM of TaqMan probe. Human GAPDH (Life Technolo-
gies, Carlsbad, CA) was used as an internal control. The
thermal cycling conditions were 2 min at 50°C, 10 min
at 95°C for denaturation, and 50 cycles at 95°C for 15 s
followed by 60°C for 60s for annealing and extension.
Presence of the fusion product was indicated by the ap-
pearance of signal above the critical threshold (Ct). All
experiments were performed in duplicate.
Results
Histopathological features
Evaluation of histopathology and group assignment took
place before the results of molecular analyses were es-
tablished. Even though all tumors (n = 27) contained a
low-grade glial element and a population of dysmorphic



















Hemorrhage Enhancement Edema Restricted
diffusion
GG01 I 6 M Cerebellar
hemisphere
Yes No No No No 0 0 + + No
GG02 I 9 F Cerebellum Yes No No n/a
GG03 I 21 F Cerebellar
hemisphere
Yes No No No Yes 0 0 ++ +++ Yes
GG04 I 9 F Medulla Yes No n/a No No 0 0 +++ 0 No
GG05 I 8 F Medulla Yes No n/a No Yes 0 0 ++ 0 n/a
GG06 I 8 M Medulla Yes No n/a No No 0 0 +++ + Yes
GG07 I 15 F MCP Yes No No No No 0 0 +++ ++ No
GG08 I 8 F Cerebellar
hemisphere
No No No No No +++ 0 + 0 No
GG09 I 11 F MCP No No n/a No Yes 0 0 ++++ 0 n/a
GG10 I 11 F Medulla No No n/a No No 0 0 ++ ++ n/a
GG11 I 12 M Medulla No No No No No 0 0 +++ ++ Yes
GG12 I 1.8 M Pons No No No No No 0 0 + ++ No
GG13 I 21 M MCP No No No No No + 0 +++ + n/a
GG14 I 0.6 M MCP No No No No No 0 0 + + No
GG15 I 15 F Cervico-
medullary
No No No n/a
GG16 I 14 M Medulla No No No No No 0 0 ++++ ++ No
GG17 II 12 M Vermis No Yes Yes - ex16:ex9 No Yes ++ 0 + 0 Yes
GG18 II 4 F Vermis No Yes Yes - ex15:ex9 Yes Yes + + +++ + Yes
GG19 II 12 F Cord
(thoraco-lumbar)
No Yes Yes - ex15:ex9 Yes No + + ++ 0 n/a
GG20 II 16 F Cord
(cervico-thoracic)
No Yes Yes - ex15:ex9 Yes Yes +++ 0 ++ +++ n/a
GG21 II 18 M Cord
(cervico-thoracic)
No Yes Yes - ex15:ex9 Yes No +++ + + ++++ n/a
GG22 II 9 F Vermis No Yes Yes - ex15:ex9 No Yes ++ 0 +++ ++ No
GG23 II 17 F Vermis No Yes Yes - ex16:ex9 No Yes ++ + + ++ Yes






















Table 1 Clinical and radiological data for two morphological groups of ganglioglioma (Continued)
GG25 II 9 M Vermis No Yes Yes - ex16:ex11 Yes No ++++ 0 ++++ + Yes
GG26 II 4 M Medulla No No No No No 0 0 +++ ++ Yes
GG27 II 9 M Midbrain No No No No Yes +++ 0 + ++ n/a
M = male; F = female.
MCP = middle cerebellar peduncle.
n/a = Not available.






















Table 2 Primers and TaqMan probes for KIAA1549-BRAF fusion gene variants
Gene fusion Primer TaqMan probe
KIAA1549-BRAF (KIAA exon 13 - BRAF exon 11) forward GGGTCCCCAGTAAGATCCAG ATCGCCATGCAGCCGATCCCGGCACCT
KIAA1549-BRAF (KIAA exon 13 - BRAF exon 11) reverse CTCGAGTCCCGTCTACCAAG
KIAA1549-BRAF (KIAA exon 15 - BRAF exon 9) forward CGTCCACAACTCAGCCTACATC ACCACAGGTTTGTCTGC
KIAA1549-BRAF (KIAA exon 15 - BRAF exon 9) reverse CCTGGAGATTTCTGTAAGGCTTTC
KIAA1549-BRAF (KIAA exon 15 - BRAF exon 11) forward AGCGATGGCACCTACAGGA CGTCCACAACTCAGCCTACATCGGATGCCCA
KIAA1549-BRAF (KIAA exon 15 - BRAF exon 11) reverse TCATCACTCGAGTCCCGTCT
KIAA1549-BRAF (KIAA exon 16 - BRAF exon 9) forward CCAGACGGCCAACAATCC ACCACAGGTTTGTCTGC
KIAA1549-BRAF (KIAA exon 16 - BRAF exon 9) reverse CCTGGAGATTTCTGTAAGGCTTTC
KIAA1549-BRAF (KIAA exon 16 - BRAF exon 10) forward CAGTGGGGGTCCTTCTACAG AGCCCAGACGGCCAACAATCCCTGCAG
KIAA1549-BRAF (KIAA exon 16 - BRAF exon 10) reverse CTTCCTTTCTCGCTGAGGTC
KIAA1549-BRAF (KIAA exon 16 - BRAF exon 11) forward AGTGGGGGTCCTTCTACAGC AGCCCAGACGGCCAACAATCCCTGCAG
KIAA1549-BRAF (KIAA exon 16 - BRAF exon 11) reverse CATGCCACTTTCCCTTGTAG
KIAA1549-BRAF (KIAA exon 17 - BRAF exon 10) forward GAATGACTCCCCCGACG ACCACAGGTTTGTCTGCTACCCCCCCTGC
KIAA1549-BRAF (KIAA exon 17 - BRAF exon 10) reverse AGGCTTTCACGTTAGTTAGTGAGC
KIAA1549-BRAF (KIAA exon 18 - BRAF exon 10) forward TGCTGCCAGAGGGATCTACTC ACCACAGGTTTGTCTGC
KIAA1549-BRAF (KIAA exon 18 - BRAF exon 10) reverse CCTGGAGATTTCTGTAAGGCTTTC
KIAA1549-BRAF (KIAA exon 19 - BRAF exon 9) forward CCAGGCTGGCCTTCGTAC ACCACAGGTTTGTCTGC
KIAA1549-BRAF (KIAA exon 19 - BRAF exon 9) reverse CCTGGAGATTTCTGTAAGGCTTTC
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lioglioma, they could be readily assigned to two groups
on the basis of their histopathological features.
Group I - classic ganglioglioma
Tumors belonging to group I (16/27; 59%) contained dys-
morphic ganglion cells and atypical glial cells, which were
admixed throughout most of the tumor (Figure 1).
Many group I tumors (13/16; 81%) exhibited aggregates
of perivascular lymphocytes. Eosinophilic granular bodies
were present in 7 of 16 tumors, but Rosenthal fibers were
present in only three tumors. The supporting matrix varied
from a reticulin-rich fibrous network, occasionally forming
a lobular configuration, to a fine fibrillary component with
variable cystic degeneration. The pleomorphism shown by
neoplastic ganglion cells in group I tumors appeared
greater than that of ganglion cells in group II tumors.
Multinucleation in ganglion cells was a feature of sev-
eral tumors in this group. The glial element in group I
tumors was varied; it showed a fibrillary phenotype in
most cases (10/16), but an admixed fibrillary and pilocy-
tic phenotype in remaining cases. The fibrillary compo-
nent diffusely infiltrated adjacent parenchyma in several
tumors. Anaplastic features, including significant mitotic
activity, were not detected, and there was no necrosis.
Group II - pilocytic astrocytoma with focal gangliocytic
differentiation
Tumors in group II (n = 11/27; 41%) were largely charac-
terized by the features of a classic pilocytic astrocytoma,but all had foci of gangliocytic differentiation (Figure 2).
All tumors displayed a glial element with a biphasic
architecture, which alternated between solid areas com-
posed of piloid cells and cystic regions showing variable
myxoid degeneration and containing disaggregated cells
with a piloid or astrocytic phenotype. Four tumors con-
tained a few areas where neoplastic glial cells showed an
oligodendroglial phenotype. Variable numbers of Rosenthal
fibers were found in the majority of tumors. Gangliocytic
differentiation manifested as distinct clusters of haphaz-
ardly arranged dysmorphic ganglion cells in just one or two
regions of the tumor. These cells were atypical and clearly
part of the neoplastic process, occurring in areas that did
not incorporate adjacent parenchyma. Bi-nucleation was a
feature of ganglion cells in two tumors. Microvascular
proliferation of the type seen in pilocytic astrocytomas
was detected in several tumors, and two contained small
foci of necrosis. The was no rosette formation.
Immunohistochemistry gave the expected results across
both groups of tumors. Many neoplastic glial cells were
GFAP-positive, while ganglion cells showed immunoreac-
tivities for MAP2, synaptophysin and neurofilament pro-
teins (Figures 1 and 2). NEU-N was expressed weakly by a
few ganglion cells in group I tumors, and to a variable ex-
tent in ganglion cells in group II tumors. Ki67 immunola-
beling was low in all tumors.
Molecular features
iFISH demonstrated BRAF duplication in 9 of 11 (82%)
group II tumors (Figure 3), but in none of the group I
a b
c d
Figure 1 Group 1 tumors – classic ganglioglioma. The classic pathologic features of a ganglioglioma are demonstrated (a, b), including
perivascular aggregates of lymphoid cells, dysmorphic ganglion cells, and a fibrillary glial cell component. Immunoreactivity for synaptophysin
highlights ganglion cells and their abnormal neuritic processes (c), while the glial component is GFAP-positive (d). All images, x200.
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strated BRAF duplication and a potential BRAF fusion, the
latter on the basis of a ‘break-apart’ probe profile that
showed one (normal) overlapping pair of signals and one
‘split’ pair of signals (Figure 3d). KIAA1549-BRAF fusions
were found in all 9 group II tumors with BRAF duplica-
tion, but in no other group I or group II tumor. Threea b
c d
Figure 2 Group II tumors - pilocytic astrocytoma with focal gangliocy
pilocytic astrocytoma (a) combines focally with collections of dysmorphic g
immunoreactivity for synaptophysin (c). An admixed GFAP-positive pilocyti
ganglion cells (d). All images, x200.KIAA1549-BRAF fusion variants were identified; exon16:
exon9, exon15:exon9, and exon16:exon11 (Table 1).
BRAF:p.V600E mutations were detected in 7 of 16 (43%)
group I tumors, but in no group II tumor. No mutations
at KRAS:p.G12 or KRAS:p.Q61 were identified across the
tumor cohort. No tumors showed evidence of an ETV6-
NTRK3 fusion.tic differentiation. The classic pathologic features of a posterior fossa
anglion cells (b). The edge of a gangliocytic nodule is highlighted by
c and fibrillary astrocytic component surrounds a few dysmorphic
a b
c d
Figure 3 Interphase fluorescence in situ hybridization analysis of the BRAF locus. FISH probe profiles (a, b, c, BRAF – red; 7p control – green;
d, centromeric BRAF – green; telomeric BRAF – red) indicate normal BRAF in GG02 (a) and a classic ‘doublet’ pattern with these probes for duplicated
BRAF in GG21 (b, arrows). In GG17 (c, d), FISH preparations indicated a complex alteration; probe profiles showed both duplication of BRAF and a
monallelic separation of duplicated BRAF.
Gupta et al. Acta Neuropathologica Communications 2014, 2:18 Page 7 of 9
http://www.actaneurocomms.org/content/2/1/18Radiological features
Of 27 patients in the study cohort, MRI with and without
contrast and diffusion-weighted imaging at presentation
were available for review in 25 and 16, respectively. Of im-
aged group I tumors, 3/14 were well-circumscribed, com-
pared to 7/11 in group II (Table 1). Among group I
tumors, the most common primary site of tumor involve-
ment was the medulla, followed by the middle cerebellar
peduncle (MCP), with secondary involvement of the pons
(8/14), MCP (5/14), cervical spinal cord (4/14), cerebellar
hemisphere (3/14) and vermis (1/14). Among group II tu-
mors, the vermis and spinal cord were the most frequent
sites of primary involvement. One group II tumor was
centered in the medulla with secondary involvement of
the MCP, pons and cervical cord, and another was cen-
tered on the midbrain with secondary thalamic involve-
ment. Three of five vermian tumors had secondary
involvement of the cerebellar hemispheres. All imaged tu-
mors enhanced, but group II tumors were more frequently
cystic or necrotic and hemorrhagic; no group I tumor
demonstrated hemorrhage on MRI. A triad of radiological
features, encompassing hemorrhage, midline location, and
the presence of cysts or necrosis, was able to separate
group I and group II tumors with a sensitivity of 91% and
specificity of 100%.
Discussion
Gangliogliomas are rare low-grade neuroepithelial tumors
of the CNS consisting of admixed mature glial andneuronal elements [2,4]. Most arise in the temporal lobe
or other supratentorial sites, but they occasionally occur
in the posterior fossa or spinal cord [2,5,6,20]. Most classic
gangliogliomas contain an idiosyncratic glial component
that combines pilocytic and fibrillary phenotypes, and in a
significant proportion of tumors this element infiltrates
surrounding parenchyma blurring the border between
tumor and normal tissue.
On the basis of our clinical experience with a few
infratentorial low-grade glioneuronal tumors that were
largely pilocytic astrocytomas but exhibited foci of gang-
liocytic differentiation, this study tested the hypothesis
that gangliogliomas of the posterior fossa and spinal
cord can be divided into distinct morphological groups
and that these groups would also be characterized by
distinct molecular alterations. In a series of 27 ganglio-
gliomas, we found that 16 (59%) had the features of a
classic ganglioglioma with admixed neuronal and glial
elements, while 11 (41%) would have been classified as
pilocytic astrocytomas, were it not for the presence of a
few circumscribed collections of cells with gangliocytic
differentiation. Our detailed review of patients’ neuroim-
aging indicated that the two groups of tumors could also
be differentiated by specific radiological characteristics; a
triad of features was able to separate the two morpho-
logic groups with 91% sensitivity and 100% specificity.
The detailed pathology of a large series of infratentorial
gangliogliomas has not been previously reported, but
one study noted that a cerebellar ganglioglioma demon-
strated a prominent pilocytic component [11].
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ations of most low-grade neuroepithelial tumors. Alter-
ations in genes involved in the MAPK pathway dominate;
KIAA1549-BRAF fusions characterize PAs, occurring in
approximately 90% of posterior fossa tumors but at lower
frequencies in spinal cord and supratentorial tumors
[12,17-19]. Some PAs demonstrate an alternative BRAF
rearrangement, where BRAF partners with another gene,
including FAM131B, MACF1, FXR1, RNF130, CLCN6,
MKRN1 and GNAI1 [17,19,21]. BRAF:p.V600E mutations
occur in PXAs (~70%), gangliogliomas (~25%), and WHO
grade II diffuse astrocytomas (~20%) [11,14,19,22,23].
Rarely, mutations of KRAS are found in a PA or grade II
diffuse glioma [12,19,24], and an ETV6-NTRK3 fusion
gene has been reported in a PXA [19]. However, such gen-
etic abnormalities were not harbored by those ganglioglio-
mas in which we were unable to show a KIAA1549-BRAF
fusion or BRAF:p.V600E mutation. Low-grade neuro-
epithelial tumors presenting in childhood rarely contain
an IDH1:p.R132H mutation. This mutation is regarded
as a hallmark of adult-type disease, but can occur in ad-
olescents with a WHO grade II diffuse glioma [19]. An-
other rare glioneuronal tumor of the posterior fossa, the
rosette-forming glioneuronal tumor of the fourth ven-
tricle, has a distinct morphology from the two types of
ganglioglioma in our study [25,26]. Additionally, it is
not characterized by KIAA1549-BRAF fusion or BRAF:
p.V600E mutation [27].
Our analysis of molecular alterations in infratentorial
gangliogliomas has revealed a clear distinction between
two morphological groups. Seven of sixteen (44%) tumors
in group I, with features of a classic ganglioglioma, har-
bored a BRAF:p.V600E mutation. This mutation is the
most common genetic alteration yet found in ganglio-
gliomas and links this infratentorial morphologic group
to typical cerebral gangliogliomas. Group II contained
tumors that were largely pilocytic astrocytomas, but
with foci of gangliocytic differentiation; 82% of these tu-
mors were characterized by a KIAA1549-BRAF fusion
gene, which is the hallmark of pilocytic astrocytomas.
Therefore, the frequency of KIAA1549-BRAF fusions in
infratentorial PAs and gangliogliomas appears very similar.
Conclusions
We have provided clear evidence of the separation of pos-
terior fossa and spinal gangliogliomas into two groups dis-
tinguished by their morphological, radiological and genetic
characteristics. One group should be regarded as classic
gangliogliomas, while on the basis of molecular data the
other might be better classified as pilocytic astrocytomas
with gangliocytic differentiation.
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